Ishan Mehta, MD
Pulmonary Disease · Atlanta, GANPI 1083903694
Payments from drug & device makers
What this record shows
3 manufacturers reported payments, led by Genentech USA, Inc. at 53.6% of the total. That places this record below the midpoint for pulmonary disease clinicians in GA, where the typical reported total is $3,789.
Across 4 payments — averaging $46.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$100
- Dompe US, Inc.$57
- Insmed, Inc.$29
Across 113 payments — averaging $1750.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dompe Farmaceutici S.p.a.$198K
What the payments were for
- Food & beverage$8646%
- Education$10054%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 1 | $100 |
| Dompe US, Inc. | 2 | $57 |
| Insmed, Inc. | 1 | $29 |
How this compares
$186 in reported general payments places this provider in the 10th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 137 | $140,478 |
| Dupixent PenDupilumab | 15 | $55,079 |
| Breo ElliptaFluticasone/Vilanterol | 66 | $47,890 |
| Arnuity ElliptaFluticasone Furoate | 94 | $31,556 |
| Advair HfaFluticasone Propion/Salmeterol | 66 | $28,591 |
| SymbicortBudesonide/Formoterol Fumarate | 49 | $19,665 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 27 | $17,649 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $15,509 |
| Spiriva RespimatTiotropium Bromide | 18 | $11,340 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $8,428 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 228 | $7,041 |
| EliquisApixaban | 11 | $4,854 |
| Pulmicort FlexhalerBudesonide | 13 | $4,657 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 53 | $4,386 |
| Wixela InhubFluticasone Propion/Salmeterol | 41 | $3,971 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Atlanta
- Colin SwensonAtlanta$255K
- Eric FlenaughAtlanta$93K
- Gregory MartinAtlanta$88K
- Victor TsengAtlanta$55K
- Ralitza MartinAtlanta$48K
- Venkatesh LakshminarayananAtlanta$33K
- Sisir AkkineniAtlanta$21K
- Gerald StatonAtlanta$21K
- Mirza AliAtlanta$16K
- Srihari VeeraraghavanAtlanta$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.